0001562180-21-001215.txt : 20210217
0001562180-21-001215.hdr.sgml : 20210217
20210217162531
ACCESSION NUMBER: 0001562180-21-001215
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210212
FILED AS OF DATE: 20210217
DATE AS OF CHANGE: 20210217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Christmas Patrick J.
CENTRAL INDEX KEY: 0001521123
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 21645155
MAIL ADDRESS:
STREET 1: C/O REGENXBIO INC.
STREET 2: 9600 BLACKWELL ROAD, SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9600 BLACKWELL ROAD
STREET 2: SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9600 BLACKWELL ROAD
STREET 2: SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-02-12
false
0001590877
REGENXBIO Inc.
RGNX
0001521123
Christmas Patrick J.
C/O REGENXBIO INC.
9600 BLACKWELL ROAD, SUITE 210
ROCKVILLE
MD
20850
false
true
false
false
Chief Legal Officer
Common Stock
2021-02-12
4
M
false
4701.00
12.10
A
21073.00
D
Common Stock
2021-02-12
4
S
false
4701.00
49.08
D
16372.00
D
Employee Stock Option (Right to Buy)
12.10
2021-02-12
4
M
false
4701.00
0.00
D
2026-08-17
Common Stock
4701.00
6430.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $49.00 to $49.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter.
/s/ Patrick J. Christmas
2021-02-17